Synyi Intelligence Completes New Strategic Financing Round and Files for Hong Kong IPO to Accelerate Panoramic Smart Healthcare Expansion

Recently, SYNYI·AI announced the successful completion of a new round of strategic financing, jointly participated in by renowned state-owned investment institutions from Beijing and Changchun, including Beijing New Airport City Fund Management Co., Ltd., Changchun New Area Equity Investment Fund Management Co., Ltd., Changchun Equity Investment Fund Management Co., Ltd., and Changchun Changfa Private Equity Fund Management Co., Ltd. This not only highlights SYNYI·AI’s rapid and healthy business growth amidst a complex economic environment but also demonstrates the company’s robust development momentum and broad market prospects.

It is worth noting that the success of this financing round is particularly remarkable given the challenging economic environment this year. This financing further solidifies SYNYI·AI’s leading position in the current capital market. The capital market’s continued confidence in the company fully demonstrates SYNYI·AI’s exceptional innovation capabilities and its significant potential for future growth.

Beijing New Airport City Fund Company is a professional investment institution under Beijing New Airport City Holdings Co., Ltd. This equity investment in SYNYI·AI represents a concrete practice of the fund company’s adherence to the “industry + investment” model. Closely aligning with the industrial development plan for the Daxing area of the Airport Economic Zone, the fund company has cultivated a unique advantage characterized by “leveraging attraction to drive investment and leveraging investment to promote industry,” thereby achieving a virtuous cycle for its industrial funds and continuously injecting “new momentum” into the region’s efforts to build a trillion-yuan airport-related industrial cluster.

Wu Qian, General Manager of Changchun New Area Industrial Investment Group Co., Ltd., spoke highly of the development of SYNYI·AI. She stated, “As a key enterprise introduced and supported by Changchun New Area, SYNYI·AI has demonstrated industry-leading technological prowess and robust business growth in the field of medical artificial intelligence. Amid the current complex economic environment, SYNYI·AI has maintained rapid growth, fully showcasing the company’s solid execution capabilities and innovative strength.”

Li Jingyan, a director at Changchun Equity Investment Fund Management Co., Ltd., also expressed strong recognition of SYNYI·AI’s future development potential. He emphasized, “The healthcare industry is currently in a critical phase of rapid transformation. We look forward to collaborating with SYNYI·AI to jointly drive the digital transformation and high-quality development of the healthcare sector.”

Over the past two years, amidst a fiercely competitive market environment, SYNYI·AI has demonstrated strong growth momentum in its market expansion efforts. The company has achieved high-speed revenue growth for three consecutive years, accompanied by a significant improvement in operational efficiency, fully highlighting its sustainable development strategy driven by technological innovation. Previously, SYNYI·AI successfully acquired Medlink (Zhejiang) Technology Co., Ltd. and Shanghai Mukang Information Technology Co., Ltd. through strategic investments. It has accumulated extensive experience and successful case studies in regional healthcare informatization and the digital transformation of high-end private medical institutions, further strengthening its capability to provide comprehensive solutions in the digital healthcare sector. Meanwhile, through deep integration of its solutions, SYNYI·AI has achieved full-scenario coverage of intelligent healthcare, spanning public hospitals, private hospitals, and medical consortia. Currently serving over 400 healthcare institution clients, the company is comprehensively advancing the digital transformation of the healthcare industry and the construction of public health systems.

Architecture Diagram

Notably, to further deepen its national strategic layout, the Northern Center of SYNYI·AI officially opened in late March 2024 at the Artificial Intelligence Industry Base within the Changchun New Area Science and Technology Innovation Plaza. It is committed to accelerating the digital transformation and intelligent upgrading of healthcare in northern China, injecting new vitality into Jilin Province’s digital transformation, and continuously establishing a first-class national benchmark for medical artificial intelligence practices.

Office Photo Gallery

Since its establishment in 2016, SYNYI·AI has been dedicated to applying digital capabilities and artificial intelligence technologies to the healthcare industry, providing AI-driven digital solutions for medical institutions, health regulatory agencies, government departments, and biomedical R&D organizations. To date, the company has launched more than 20 innovative digital-intelligence solutions, covering dozens of specialized vertical fields such as data management, intelligent diagnosis, operational management, and clinical research, thereby providing strong support for the intelligent transformation of the healthcare industry.

Moreover, leveraging years of accumulated expertise in medical natural language processing and combining it with practical experience in vertical healthcare scenarios, SYNYI·AI pioneered the release of its self-developed generative language model for medical records in April 2023. This innovative achievement has not only garnered widespread attention from the industry but also been successfully included in the "2024 Typical Demonstration Application Cases of Large Models" published by the China Academy of Information and Communications Technology (CAICT), fully demonstrating the company's strength in exploring cutting-edge technologies.

“Technological innovation is the core driver of SYNYI·AI’s sustained growth,” stated Dr. Zhang Shaodian, Founder and Chairman of SYNYI·AI. “SYNYI·AI will continue to uphold its corporate mission of ‘optimizing every medical decision,’ constantly promoting the application and practice of medical big data and artificial intelligence technologies in innovative healthcare scenarios. In the future, the company will steadily increase its R&D investment, expand technological boundaries and application scenarios, and drive the digital transformation and intelligent upgrading of the healthcare industry.”